***All Objectives Successfully Met*** Conference Call to Be Held Today at 10 am Eastern Time SEATTLE, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ: ATOS ), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, reported preliminary results from its Phase 1 dose- escalation study of its proprietary topical Endoxifen in male subjects. All objectives were successfully met: "Based on these positive preliminary results, we are advancing our topical Endoxifen into a Phase 2 study to reduce gynecomastia in men starting prostate cancer therapy," commented Dr. Steven C. Quay, CEO and President. "We anticipate retaining a clinical research organization to manage that study in the fourth quarter 2018.